Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ...

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Green tea may boost heart and brain health, regulate blood sugar, and more. Learn more about green tea's health benefits, ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, ...

Pomegranate extract shows promise in lowering systolic blood pressure and inflammatory markers, highlighting its role in ...

Neurologists know that exercise benefits the brain by increasing blood flow and ferrying oxygen to it. Even a small dose of ...

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

Though high cholesterol may contribute to the risk of developing Alzheimer’s disease or a related dementia (ADRD), taking a ...

Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting ...

Researchers conducted a post hoc analysis of the PIONEER trials to compare the efficacy of oral semaglutide versus active comparators in improving T2D cardiometabolic outcomes.